Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Samsung Bioepis
Pharma
WuXi, Daiichi-Novartis, Merck KGaA-Abbisko—Fierce Pharma Asia
WuXi Bio's stock plummeted. Daiichi Sankyo and Novartis shook hands on BRAF patent dispute. Merck KGaA signs tumor drug licensing deal with Abbisko.
Angus Liu
Dec 8, 2023 8:13am
J&J, Samsung Bioepis ink Stelara biosimilar settlement
Nov 30, 2023 4:48pm
Otsuka, Astellas, Exelixis and Insilico—Fierce Pharma Asia
Sep 15, 2023 9:00am
Sandoz inks deal to commercialize biosim to J&J's Stelara
Sep 11, 2023 11:45am
BMS-BeiGene, Sumitomo-Otsuka, AstraZeneca—Fierce Pharma Asia
Aug 4, 2023 8:50am
Samsung Bioepis looks to acquire Biogen's biosim unit: reports
Aug 2, 2023 3:49pm